London: Britain announced on Friday that it would offer new vaccinations to the thousands of people who volunteered for testing novavax Coronavirus vaccine, which has not yet been approved for use in any country.
Around 15,000 people in the UK received Novavax shots as part of a clinical trial. While the UK recognizes them as a form of vaccination, most countries do not, which means they cannot travel.
The UK Department of Health said more than 15,000 participants would be given two doses of the Pfizer/BioNTech vaccine. The government says it plans to expand the offer to around 6,000 UK participants in trials of other vaccines that have not been approved for use.
Britain has appealed to other members of the Group of 20 countries to classify clinical trial volunteers as vaccinated, but most have not.
England’s deputy chief medical officer, Jonathan Van-Tam, said these measures would not be necessary if more countries around the world had allowed UK volunteers to travel abroad to enjoy full immunization status. would have been.
In June, Novavax announced that its vaccine was found to be about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the US and Mexico.
US-based Novavax has asked the World Health Organization to approve its COVID-19 vaccine for emergency use so that it can be part of kovax Global Vaccine Program. But it has delayed obtaining approval in Europe or United States of america.
Novavax shots are easier to store and transport than some other options, and have long been expected to play a key role in increasing supplies in poor countries desperate for more vaccine doses.
Around 15,000 people in the UK received Novavax shots as part of a clinical trial. While the UK recognizes them as a form of vaccination, most countries do not, which means they cannot travel.
The UK Department of Health said more than 15,000 participants would be given two doses of the Pfizer/BioNTech vaccine. The government says it plans to expand the offer to around 6,000 UK participants in trials of other vaccines that have not been approved for use.
Britain has appealed to other members of the Group of 20 countries to classify clinical trial volunteers as vaccinated, but most have not.
England’s deputy chief medical officer, Jonathan Van-Tam, said these measures would not be necessary if more countries around the world had allowed UK volunteers to travel abroad to enjoy full immunization status. would have been.
In June, Novavax announced that its vaccine was found to be about 90% effective against symptomatic COVID-19 in a study of nearly 30,000 people in the US and Mexico.
US-based Novavax has asked the World Health Organization to approve its COVID-19 vaccine for emergency use so that it can be part of kovax Global Vaccine Program. But it has delayed obtaining approval in Europe or United States of america.
Novavax shots are easier to store and transport than some other options, and have long been expected to play a key role in increasing supplies in poor countries desperate for more vaccine doses.
.